Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eli Lilly and Company is conducting a Phase 3 clinical study titled ‘Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3).’ The study aims to evaluate the efficacy and safety of retatrutide, a potential treatment for individuals with Type 2 Diabetes who also suffer from renal impairment and have inadequate glycemic control.
The intervention being tested is retatrutide, administered subcutaneously, which is compared against a placebo. Retatrutide is designed to improve glycemic control in patients struggling with Type 2 Diabetes and renal issues.
This study is interventional, randomized, and follows a parallel assignment model. It employs double masking, meaning both participants and investigators are unaware of the treatment allocations. The primary purpose of the study is treatment-focused.
The study began on March 15, 2024, and the last update was submitted on July 22, 2025. These dates are crucial as they mark the progression and ongoing status of the study, which is still recruiting participants.
For investors, this study could signal potential growth in Eli Lilly’s market value, particularly if retatrutide proves effective. The success of this treatment could enhance Eli Lilly’s competitive position in the diabetes market, influencing stock performance positively.
The study is ongoing, with further details available on the ClinicalTrials portal.